Furthermore, CRC cell lines expressing higher levels of pY88 paxillin are more sensitive to killing by Src inhibitor dasatinib, suggesting that pY88 paxillin may be exploited as a predictive biomarker for drugs targeting Src. Here, PXN is linked to colorectal carcinoma.